Anissah Insyirah Idris, '- (2021) Studi Penggunaan Deksametason Pada Pasien Covid-19 Derajat Berat Dengan Komorbid Diabetes Mellitus (Penelitian di Rumah Sakit Bhayangkara H.S. Samsoeri Mertojoso Surabaya). Skripsi thesis, Universitas Airlangga.

	Text (HALAMAN DEPAN) 1. JUDUL.pdf Download (1MB)
	Text (ABSTRAK) 2. ABSTRACT.pdf Download (135kB)
	Text (DAFTAR ISI) 3. DAFTAR ISI.pdf Download (550kB)
	Text (BAB I PENDAHULUAN) 4. BAB I PENDAHULUAN.pdf Download (154kB)
	Text (BAB II TINJAUAN PUSTAKA) 5. BAB II TINJAUAN PUSTAKA.pdf Restricted to Registered users only Download (773kB) | Request a copy
	Text (BAB III KERANGKA KONSEP) 6. BAB III KERANGKA KONSEP.pdf Restricted to Registered users only Download (137kB) | Request a copy
	Text (BAB IV METODE PENLITIAN) 7. BAB IV METODE PENELITIAN.pdf Restricted to Registered users only Download (165kB) | Request a copy
	Text (BAB V HASIL PENELITIAN) 8. BAB V HASIL PENELITIAN DAN PEMBAHASAN.pdf Restricted to Registered users only Download (471kB) | Request a copy
	Text (BAB VI KESIMPULAN DAN SARAN) 9. BAB VI KESIMPULAN DAN SARAN.pdf Restricted to Registered users only Download (133kB) | Request a copy
	Text (DAFTAR PUSTAKA) 10. DAFTAR PUSTAKA.pdf Download (284kB)
	Text (LAMPIRAN) 11 LAMPIRAN.pdf Restricted to Registered users only Download (710kB) | Request a copy
	Text (KESEDIAAN PUBLIKASI) KESEDIAAN PUBLIKASI.pdf Restricted to Registered users only Download (313kB) | Request a copy

Abstract

Coronavirus Disease 2019 is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 that has never been found in humans before. Diabetes mellitus (DM) is a comorbid that becomes as major risk factors that can worsen the symptoms and increase the severity in COVID-19’s patients. Dexamethasone is used as anti-inflammatory agent to treat inflammation caused by cytokine storms. However, dexamethasone can increase blood glucose concentrations in COVID-19 patients with comorbid DM due to glucocorticoids effects. This study aims to determine the effectiveness and how it regulates blood glucose in severe COVID-19 patients with comorbid DM who use dexamethasone. This study is a descriptive observational study using retrospective data from Bhayangkara HS Samsoeri Mertojoso Hospital Surabaya from September 2020 - February 2021. The results of the study on 27 patients who met the inclusion criteria showed that administering Dexamethasone (1 x 6 mg) IV was effective in severe COVID-19’s patient with comorbid DM based on length of hospitalization of 13 days, 14 days, and 12 days, respectively; improvement of clinical condition of oxygen saturation by 91%, 100%, 100%; RT-PCR/Rapid Ag became negative 74%, 100%, 100%; and improvement of chest x-ray results by 83%, 33%, 100%, respectively. The glucocorticoid effect of dexamethasone in comorbid DM patients is regulated by administration of long-acting insulin, rapid-acting insulin and oral anti-diabetic. Based on the description above, the use of dexamethasone therapy for severe COVID-19 patients with comorbid DM is already appropriate with the patient's clinical condition and literature.

Actions (login required)

View Item